Scientists Fine-Tune Clot-Busting drug for brain hemorrhage in the lab
NCT ID NCT07411079
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study uses blood samples from over 1,100 people to create artificial clots in the lab, mimicking brain hemorrhages. Researchers test a modified clot-busting drug (rtPA) to find the best dose for different bleeding risks. The goal is to improve clot removal and guide future treatments for this serious condition.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
modified tissue plasminogen activator (rtPA)
What this could lead to
If successful, this could lead to personalized dosing of clot-busting drugs for brain hemorrhage patients, potentially improving clot removal and reducing disability.
What could go wrong
This is an early lab study using artificial clots, not real patients. Results may not translate to actual treatment, and the drug's safety and effectiveness in people remain unproven.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INTRACEREBRAL HEMORRHAGE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHU de Lille
RECRUITINGLille, 59000, France
Contact Phone: •••-•••-•••• Email: •••••@•••••